← Back to Search

Prostaglandin Analog

TC-002 for Glaucoma (TC-002-301 Trial)

Phase 3
Waitlist Available
Research Sponsored by TearClear Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group

Summary

This trial is testing two types of eye drops containing latanoprost in people with high eye pressure to prevent glaucoma. The drops work by helping fluid drain from the eye, lowering the pressure.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TC-002Experimental Treatment1 Intervention
TC-002, TearClear latanoprost ophthalmic solution, 0.005%
Group II: LAT, 0.005%Active Control1 Intervention
Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%

Find a Location

Who is running the clinical trial?

TearClear CorpLead Sponsor
~75 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top